Table 1.
Study design and clinical characteristics of FHS samples.
| Clinical characteristics | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Group 6 | Group 7 | Group 8 |
|---|---|---|---|---|---|---|---|---|
| Obesity* | – | – | – | – | + | + | + | + |
| Dyslipidemia* | – | – | + | + | – | – | + | + |
| Dysglycemia* | – | + | – | + | – | + | – | + |
| Sample size (n) | 84 | 83 | 84 | 84 | 82 | 84 | 74 | 83 |
| Age (years) | 52 ± 14 | 54 ± 13 | 52 ± 14 | 54 ± 15 | 53 ± 12 | 54 ± 11 | 50 ± 14 | 55 ± 13 |
| Women (%) | 50 | 49 | 50 | 50 | 50 | 50 | 57 | 49 |
| BMI (kg/m2) | 24.5 ± 2.8 | 25.0 ± 2.7 | 25.9 ± 2.7 | 26.6 ± 2.3 | 32.4 ± 2.3 | 35.9 ± 5.1 | 35.4 ± 4.8 | 34.9 ± 4.9 |
| HDL-C (mg/dL) | 65 ± 18 | 62 ± 15 | 45 ± 11 | 44 ± 14 | 61 ± 13 | 58 ± 13 | 42 ± 10 | 42 ± 10 |
| TAG (mg/dL) | 81 ± 26 | 84 ± 26 | 167 ± 115 | 175 ± 91 | 92 ± 28 | 95 ± 29 | 165 ± 77 | 202 ± 148 |
| Glucose (mg/dL) | 92 ± 5 | 107 ± 15 | 92 ± 5 | 107 ± 7 | 93 ± 4 | 109 ± 7 | 93 ± 5 | 122 ± 37 |
⁎
(+) and (-) represent the presence and absence, respectively, of obesity, dysglycemia, and dyslipidemia in each of the eight metabolic risk factor groups. Obesity was defined as BMI ≥30 kg/m2. Dysglycemia was defined as fasting blood glucose ≥100 mg/dL. Dyslipidemia was defined as either TAG ≥150 mg/dL or HDL-C <40 mg/dL in men or <50 mg/dL in women.